Findings

What do systematic reviews say?

1,923 questions · 1,956 findings · 143 reviews · Musculoskeletal

Sort:Best matchNewestHighest certainty Download CSV

No studies found 555 · 28.4%GRADE not reported 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%

SMP vs non‐SMP intervention

Global OA scores WOMAC. Scale from 0 to 240. Lower score is better. · patients with osteoarthritis

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
98 participants
Moderate

SMP vs non‐SMP intervention

Function—Self‐reported Multiple tools3. Scale from 0 to 68. Lower score is better. · patients with osteoarthritis

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
216 participants
Moderate

Quality of life measured on multiple scales (0 to 100; higher score = better quality of life) Postintervention: first assessment after end of treatment; no later than 3 months · patients with osteoarthritis

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
226 participants
Moderate

SMP vs non‐SMP intervention

Withdrawals Losses to · patients with osteoarthritis

SMP showed no clear difference in withdrawals Losses to compared with non‐SMP intervention (moderate certainty).

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
RR 0.86 [0.69, 1.09]
919 participants
Moderate

SMP vs attention control

Pain Multiple tools4. Scale from: 0 to 10, 0 = no pain · patients with osteoarthritis

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
575 participants
Low

SMP vs attention control

Global OA scores AIMS2 (average of physical, affect, and pain subscales). Scale from 0 to 10, lower better · patients with osteoarthritis

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
251 participants
Low

SMP vs attention control

Function—Self‐reported Multiple tools3. Scale from 0 to 68. Lower score is better. · patients with osteoarthritis

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
574 participants
Low

SMP vs attention control

Quality of life or psychological well‐being (higher = higher quality of life or psychological well‐being): end‐of‐intervention · patients with osteoarthritis

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
165 participants
Low

SMP vs attention control

Treatment withdrawal · patients with osteoarthritis

SMP showed no clear difference in withdrawals compared with attention control (moderate certainty).

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
RR 1.11 [0.78, 1.57]
937 participants
Moderate

SMP vs usual care

Self‐management of OA Multiple tools1. Scale from 1 to 10, higher better · patients with osteoarthritis

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 1706 participants
Moderate

SMP vs usual care

Positive and active engagement in life heiQ subscale for positive and active engagement in life. Scale from 1 to 6 (higher better) · patients with osteoarthritis

1 finding from 1 review

Self‐management education programmes for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
357 participants
Moderate

Canakinumab vs triamcinolone acetonide

Pain: at 72 hours (canakinumab 150 mg) · acute gout

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 443 participants
Moderate

Rilonacept vs indomethacin

Functional disability at 3 months ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rilonacept vs indomethacin

Health‐related quality of life ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rilonacept vs indomethacin

Participant global assessment of success Not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rilonacept vs indomethacin

Withdrawals due to adverse events · acute gout

Rilonacept showed no clear difference in adverse events ‐ study withdrawals due to adverse events compared with indomethacin (low certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 0.51 [0.05, 5.47]
1 study · 151 participants
Low

Rilonacept vs indomethacin

Adverse events as N of participants with at least one adverse event objective · acute gout

Rilonacept showed no clear difference in adverse events ‐ participants with at least 1 adverse event compared with indomethacin (low certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.19 [0.75, 1.88]
1 study · 151 participants
Low

Canakinumab vs triamcinolone acetonide

Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout

Canakinumab probably leads to higher inflammation: participants with no swelling at 72 hours (canakinumab… compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
RR 1.39 [1.11, 1.74]
3 studies · 523 participants
Moderate

Canakinumab vs triamcinolone acetonide

Functional disability at 3 months ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs triamcinolone acetonide

Health‐related quality of life ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐1 inhibitors for acute gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found